These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 19303106

  • 1. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
    Dos Reis ST, Pontes J, Villanova FE, Borra PM, Antunes AA, Dall'oglio MF, Srougi M, Leite KR.
    J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer.
    dos Reis ST, Villanova FE, Andrade PM, Pontes J, de Sousa-Canavez JM, Sañudo A, Antunes AA, Dall'oglio MF, Srougi M, Moreira Leite KR.
    Urol Oncol; 2010 May; 28(6):624-7. PubMed ID: 19117773
    [Abstract] [Full Text] [Related]

  • 3. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK.
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [Abstract] [Full Text] [Related]

  • 4. Matrix metalloproteinases 1, 2, 3 and 9 functional single-nucleotide polymorphisms in idiopathic recurrent spontaneous abortion.
    Pereza N, Ostojić S, Volk M, Kapović M, Peterlin B.
    Reprod Biomed Online; 2012 May; 24(5):567-75. PubMed ID: 22406112
    [Abstract] [Full Text] [Related]

  • 5. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk.
    Peng B, Cao L, Ma X, Wang W, Wang D, Yu L.
    Mutagenesis; 2010 Jul; 25(4):371-9. PubMed ID: 20360147
    [Abstract] [Full Text] [Related]

  • 6. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer.
    Woo M, Park K, Nam J, Kim JC.
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1064-70. PubMed ID: 17608852
    [Abstract] [Full Text] [Related]

  • 7. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
    Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P, Försti A.
    Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
    [Abstract] [Full Text] [Related]

  • 8. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis.
    Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, Xiong W, Xu Y, Zhao J.
    Gene; 2013 Mar 15; 517(1):65-71. PubMed ID: 23313298
    [Abstract] [Full Text] [Related]

  • 9. Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma.
    Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, Zhang X, Dong X, He Y, Yao K, Zhang H, Peng Y, Yuan X, Zhi L, Zhang X, He F.
    Hum Mutat; 2007 Nov 15; 28(11):1091-7. PubMed ID: 17607721
    [Abstract] [Full Text] [Related]

  • 10. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H.
    Cancer; 2003 Oct 01; 98(7):1411-6. PubMed ID: 14508827
    [Abstract] [Full Text] [Related]

  • 11. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer.
    O-Charoenrat P, Khantapura P.
    Oral Oncol; 2006 Mar 01; 42(3):257-67. PubMed ID: 16275157
    [Abstract] [Full Text] [Related]

  • 12. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
    Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J.
    Cancer Epidemiol Biomarkers Prev; 2004 May 01; 13(5):759-64. PubMed ID: 15159307
    [Abstract] [Full Text] [Related]

  • 13. TSP1 and MMP9 genetic variants in sporadic prostate cancer.
    Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L.
    Cancer Genet Cytogenet; 2007 Jan 01; 172(1):38-44. PubMed ID: 17175378
    [Abstract] [Full Text] [Related]

  • 14. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
    Shaik AP, Jamil K, Das P.
    Urol J; 2009 Jan 01; 6(2):78-86. PubMed ID: 19472123
    [Abstract] [Full Text] [Related]

  • 15. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes.
    Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D.
    Carcinogenesis; 2004 Mar 01; 25(3):399-404. PubMed ID: 14604886
    [Abstract] [Full Text] [Related]

  • 16. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population.
    Albayrak S, Cangüven O, Göktaş C, Aydemir H, Köksal V.
    Urol Int; 2007 Mar 01; 79(4):312-5. PubMed ID: 18025848
    [Abstract] [Full Text] [Related]

  • 17. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease.
    Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, Southwick A, Myers RM, Iribarren C, Fortmann SP, Go AS, Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study.
    Am Heart J; 2007 Dec 01; 154(6):1043-51. PubMed ID: 18035073
    [Abstract] [Full Text] [Related]

  • 18. [Polymorphism in promoter regions of matrix metalloproteinases (MMP1, MMP9, and MMP12) in chronic obstructive pulmonary disease patients].
    Korytina GF, Akhmadishina LZ, Ianbaeva DG, Viktorova TV.
    Genetika; 2008 Feb 01; 44(2):242-9. PubMed ID: 18619044
    [Abstract] [Full Text] [Related]

  • 19. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
    Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J.
    Prostate Cancer Prostatic Dis; 2004 Feb 01; 7(4):327-32. PubMed ID: 15356679
    [Abstract] [Full Text] [Related]

  • 20. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility.
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R.
    Clin Cancer Res; 2002 Dec 01; 8(12):3820-3. PubMed ID: 12473595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.